Abstract:Neoantigens play a crucial role in cancer immunotherapy. However, the effectiveness and safety of neoantigen-based immunotherapies in patients with colorectal cancer (CRC), particularly in the Chinese population, have not been well studied. This study explored the feasibility and effectiveness of neoantigens in the treatment of CRC. Whole-exome sequencing (WES) and transcriptome sequencing were used to identify somatic mutations, RNA expression, and human leukocyte antigen (HLA) alleles. Neoantigen candidates … Show more
“…HLA genotypes are also significant information for deterring the affinity of presentation and binding in subsequent steps ( 101 ). Computational approaches based on machine learning algorithms such as NetMHCpan, NetMHCIIpan, and MuPeXI predict and prioritize neopeptides ( 26 ).…”
Colorectal cancer (CRC) is one of the most common cancers worldwide. Current therapies such as surgery, chemotherapy, and radiotherapy encounter obstacles in preventing metastasis of CRC even when applied in combination. Immune checkpoint inhibitors depict limited effects due to the limited cases of CRC patients with high microsatellite instability (MSI-H). Cancer vaccines are designed to trigger the elevation of tumor-infiltrated lymphocytes, resulting in the intense response of the immune system to tumor antigens. This review briefly summarizes different categories of CRC vaccines, demonstrates the current outcomes of relevant clinical trials, and provides particular focus on recent advances on nanovaccines and neoantigen vaccines, representing the trend and emphasis of CRC vaccine development.
“…HLA genotypes are also significant information for deterring the affinity of presentation and binding in subsequent steps ( 101 ). Computational approaches based on machine learning algorithms such as NetMHCpan, NetMHCIIpan, and MuPeXI predict and prioritize neopeptides ( 26 ).…”
Colorectal cancer (CRC) is one of the most common cancers worldwide. Current therapies such as surgery, chemotherapy, and radiotherapy encounter obstacles in preventing metastasis of CRC even when applied in combination. Immune checkpoint inhibitors depict limited effects due to the limited cases of CRC patients with high microsatellite instability (MSI-H). Cancer vaccines are designed to trigger the elevation of tumor-infiltrated lymphocytes, resulting in the intense response of the immune system to tumor antigens. This review briefly summarizes different categories of CRC vaccines, demonstrates the current outcomes of relevant clinical trials, and provides particular focus on recent advances on nanovaccines and neoantigen vaccines, representing the trend and emphasis of CRC vaccine development.
“…Out of the 26 targets, only one neoepitope tested to be reactive in studies using the patient cells. The low specificity of neoantigen identification is recognized within the field and has directed investigations into novel identification methods meant to improve the viability of therapeutic neoantigen targeting [39][40][41][42][43].…”
Section: Neoantigen Identification and Selectionmentioning
confidence: 99%
“…Research efforts have been established to explore the feasibility of neoantigen-based immunotherapeutic approaches in a wide spectrum of cancer types. These include the expansion of research studies to include common high-risk malignancies such as gastric [42], colorectal [40], bladder [98], and lung cancer [99].…”
Alternatives to conventional cancer treatments are highly sought after for high-risk malignancies that have a poor response to established treatment modalities. With research advancing rapidly in the past decade, neoantigen-based immunotherapeutic approaches represent an effective and highly tolerable therapeutic option. Neoantigens are tumor-specific antigens that are not expressed in normal cells and possess significant immunogenic potential. Several recent studies have described the conceptual framework and methodologies to generate neoantigen-based vaccines as well as the formulation of appropriate clinical trials to advance this approach for patient care. This review aims to describe some of the key studies in the recent literature in this rapidly evolving field and summarize the current advances in neoantigen identification and selection, vaccine generation and delivery, and the optimization of neoantigen-based therapeutic strategies, including the early data from pivotal clinical studies.
“…They have used transcriptome sequencing and WES and specified various neoantigens (TSHZ3-L523P, NRAS-G12D, TP53-R248W, EYA2-V333I, RARAR83H, TASP1-P161L, MOSPD1-V63I, RAP1GAP-S215R, SEC11A-R11L, NAV2-D1973N, HAVCR2-F39V, SMPDL3BT452M, ULK1-S248L, and LRFN3-R118Q) eliciting a heightened neoantigen-reactive T cell (NRT) response. Moreover, based on their findings, neoantigen-containing peptides ULK1-S248L and SEC11A-R11L from HLA-A0201 + PW11 induced specific CTL responses more effectively [143]. Most recently, a personalized immunopeptidome analysis introduced by Minegishi et al significantly facilitated direct identification of neoantigens and was promised as a novel landscape of immunopeptides diagnosis for further application in cancer immunotherapy [144].…”
Section: Neoantigens Derived From Colorectal Cancermentioning
Background
Tumor-specific neoantigens are ideal targets for cancer immunotherapy. As research findings have proved, neoantigen-specific T cell activity is immunotherapy’s most important determinant.
Main text
There is sufficient evidence showing the role of neoantigens in clinically successful immunotherapy, providing a justification for targeting. Because of the significance of the pre-existing anti-tumor immune response for the immune checkpoint inhibitor, it is believed that personalized neoantigen-based therapy may be an imperative approach for cancer therapy. Thus, intensive attention is given to strategies targeting neoantigens for the significant impact with other immunotherapies, such as the immune checkpoint inhibitor. Today, several algorithms are designed and optimized based on Next-Generation Sequencing and public databases, including dbPepNeo, TANTIGEN 2.0, Cancer Antigenic Peptide Database, NEPdb, and CEDAR databases for predicting neoantigens in silico that stimulates the development of T cell therapies, cancer vaccine, and other ongoing immunotherapy approaches.
Conclusions
In this review, we deliberated the current developments in understanding and recognition of the immunogenicity of newly found gastrointestinal neoantigens as well as their functions in immunotherapies and cancer detection. We also described how neoantigens are being developed and how they might be used in the treatment of GI malignancies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.